Study identification

EU PAS number

EUPAS41161

Study ID

44945

Official title and acronym

Characterisation of the Australian adult population living with asthma: Exacerbation frequency, long-term OCS use and adverse effects.

DARWIN EU® study

No

Study countries

Australia

Study description

The study employs a novel multi-modal approach to analyse, describe, and categorise the Australian adult asthmatic population based on factors such as their age, exacerbation frequency and OCS reliance. An audit of asthma classification and management in the primary care setting will also be conducted simultaneously. Understanding the demographics of Australian adults diagnosed with asthma and assessing existing management practices in primary care stands to offer insights into the burden of the disease in this country and how it could be reduced. The results of this study stand to be beneficial for both the patient’s and the health care sector as identifying gaps in the management of asthma in the primary care setting can improve patient's asthma control thereby easing the burden on the Australian health care sector by limiting the number of avoidable asthma-related hospitalisations per year.

Study status

Ongoing
Research institutions and networks

Institutions

Networks

Respiratory Effectiveness Group (REG)
Belgium
Denmark
France
Germany
Greece
Hungary
Italy
Netherlands
Spain
Sweden
United Kingdom
First published:
04/06/2024
Network
ENCePP partner

Contact details

David Price

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Date of final study report

Planned:
Sources of funding
Other
Pharmaceutical company and other private sector 

More details on funding

AstraZeneca, Novartis, Optimum Patient Care Australia
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable